

# Comparison of “Indicator conditions” versus “universal testing” strategies for HIV detection in primary care centers.

Ignacio Menacho<sup>1</sup>, Ethel Sequeira<sup>2</sup>, Mercè Muns<sup>3</sup>, Olga Barba<sup>4</sup>, Thaïs Clusa<sup>2</sup>, Lorna Leal<sup>5</sup>, Emma Fernández<sup>5</sup>, Dorte Raben<sup>6</sup>, Jens Lundgren<sup>6</sup>, Ignacio Pérez<sup>5</sup>, Felipe García<sup>5</sup>, Jose María Gatell<sup>5</sup>, **Agathe León**<sup>5</sup> for UCC and HIV Indicator Diseases Across Europe Study Group.

<sup>1</sup>CAP Les Corts, <sup>2</sup>CAPSE Casanova, <sup>3</sup>CAP Raval Sud, <sup>4</sup>CAPSE Rosellón, <sup>5</sup>Infectious Diseases Unit, Hospital Clinic, Barcelona, <sup>6</sup>HIV Indicator Diseases Across Europe

# Objectives

In primary care centers:

1. To test all persons with 4 selected indicator conditions (Indicator strategy).

2. To test in a randomly selected sample (1/10) the remaining patients attending these centers (Universal strategy).

# Methods

- A multicenter, prospective study in 4 Primary Care Centers (PCC) of Barcelona was undertaken (September 2009-March 2011)
- Eligible patients: 18-65 years old.

<b>Indicator strategy</b>	<b>Universal strategy</b>
Herpes Zoster Seborrheic Eczema Mononucleosis S Leucopenia/Thrombopenia >4 weeks	1 of every 10 randomly selected patients visited for other than the previous indicator conditions.

# Methods

- Written inform consent.
- Questionnaires: Sociodemographic and sexual behavior; HIV testing history and clinical information.
- Patients recruited in indicator strategy were included in HIDES I of HIV in Europe.
- Blood rapid test (Determine® HIV-1/2 Ag/ Ab Combo)  
Cost for 1 test: 6€.
- Education and training of staff involved

# Results

Indicator strategy	Universal Strategy
Primary Care census with the 4 selected indicators <b>775</b> Offered screening* 89 Accepted screening 85 Completed testing <b>85</b>	Primary Care census <b>66043</b> Offered screening (random selection 1/10)* 344 Accepted screening 313 Completed testing <b>304</b>

\*Only committed participating physicians during selected periods of the week

Indicator strategy		Universal Strategy	
Census	Offer rate	Census	Offer rate
<b>775</b>	<b>11.5 %</b>	66043	<b>0.5%</b>
Offered screening	Acceptance R	Offered screening	Acceptance R
89	94.4%	344	90.9%
Accepted Scre.	Completion R	Accepted Scre.	Completion R
85	100%	313	97.1%
Completed testing	Overall rate	Completed testing	Overall rate
85	10.9%	304	0.46%

# Comparison baseline characteristics

Variable	Indicator	Universal	P
<b>Age*</b>	36 (30-50)	35 (28-49)	0,85
<b>Male**</b>	60 (71)	117 (39)	<b>0,0001</b>
<b>PCC**</b>			
<b>C1, C2, C3</b>	38 (45)	261 (86)	<b>0,0001</b>
<b>C4</b>	47 (55)	42 (14)	
<b>MSM*</b>	8 (9)	16 (5)	0,27
<b>Never used Condoms *</b>	42 (49)	128 (42)	<b>0,002</b>
<b>Previous STD</b>	12 (14 )	19 (6)	<b>0,021</b>
<b>Nº 3-5 Visits HCS</b>	6 (7)	1 (0.3)	<b>0,0001</b>
<b>Previous HIV test</b>	29 (34)	123 (41)	0,12

\*: Number (%). \*\*:Median (IQR).

# HIV prevalence

Indicator strategy	Universal strategy
<p data-bbox="241 659 1037 738">Completed testing: 85</p> <p data-bbox="371 898 907 962">HIV Positive: 4</p> <p data-bbox="423 1137 855 1201"><b>Prevalence</b></p> <p data-bbox="210 1257 1070 1337"><b>4.7% (95%CI: 1.3-11.6)</b></p> <p data-bbox="931 1369 1256 1441">P= 0.009</p>	<p data-bbox="1193 659 2040 738">Completed testing: 304</p> <p data-bbox="1346 898 1872 962">HIV Positive: 1</p> <p data-bbox="1397 1137 1830 1201"><b>Prevalence</b></p> <p data-bbox="1160 1257 2069 1337"><b>0.3% (95%CI: 0.01-1.82)</b></p>



# Baseline characteristics of HIV newly diagnosed

Variable	Indicator n=4	Universal n=1
<b>Male</b>	4	1
<b>Median Age</b>	38	32
<b>PCC</b>	C4	C2
<b>Caucasian</b>	3	1
<b>MSM</b>	3	1
<b>1-3 Visits to HCS</b>	4	1
<b>Actual ID</b>		
<b>MNS</b>	2	Dermatitis
<b>L/T</b>	2	
<b>≥4 sexual partners/year</b>	3	1
<b>Previous STD</b>	3	1
<b>Previous HIV test</b>	3	1

# Direct cost per new HIV diagnosis

<b>Indicator strategy</b>	<b>Universal strategy</b>
<p>HIV Prevalence 4.7% (95%CI: 1.3-11.6) Primary Care census 775 Potential HIV + <b>36 (95%CI: 25-49)</b> Overall Cost 4,650 euros <b>Cost per HIV diagnosis</b> <b>129€ (95%CI: 107-153)</b></p>	<p>HIV Prevalence 0.3% (95%CI: 0.01-1.82) Primary Care census 66043 Potential HIV + <b>198 (95%CI: 171-227)</b> Overall Cost 396,258 euros <b>Cost per HIV diagnosis</b> <b>2,001€ (95%CI: 1,913-2,088)</b></p>

# Discussion: Comparison with HIDES I

## Indicator strategy

HIV Prevalence

4.7% (95%CI: 1.3-11.6)

HIDES I MON+CYT combined (n=535)

**3.7% (95%CI: 2.3-5.7)**

Potential HIV +

**28 (95%CI: 18-40)**

Direct Cost per HIV diagnosis

**166€ (95%CI: 141-193)**

# Conclusions

Four selected indicators condition-guided HIV testing, seems to be feasible and less costly (direct cost) strategy to improve diagnosis of HIV infection than in universal population in our environment.